Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19427323 | 0.78 | CYP1A2 (0.43) | LMNACHRM2CHRM4CHRM5THRB | |
| SCHEMBL12015352 | 0.75 | ITGB1 (0.39) | RIPK1KMT2ALMNATHRBBLM | |
| SCHEMBL19421534 | 0.73 | NPC1 (0.34) | NPSR1CYP1A2TDP1 | |
| SCHEMBL14752964 | 0.73 | CHRNB2 (0.40) | KMT2ALMNABLMNPSR1HPGD | |
| SCHEMBL12015351 | 0.72 | LMNA (0.53) | RIPK1KMT2ALMNATHRBBLM | |
| SCHEMBL12015371 | 0.71 | SMN1; SMN2 (0.51) | RIPK1KMT2ALMNATHRBBLM | |
| SCHEMBL17898504 | 0.71 | TP53 (0.35) | RIPK1KMT2ALMNACYP1A2 | |
| SCHEMBL17898502 | 0.69 | KMT2A (0.32) | RIPK1KMT2A | |
| SCHEMBL12015370 | 0.69 | SMN1; SMN2 (0.54) | RIPK1KMT2ALMNATHRBBLM | |
| SCHEMBL13621185 | 0.68 | L3MBTL1 (0.35) | KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, CLN6 | RIPK1 4241/4885KMT2A 2904/4885LMNA 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.